Search

For 2019, 29 EU/EEA countries reported 8 313 confirmed cases of Shiga toxin-producing Escherichia coli (STEC) infection.

This report presents the results of the fourth round of the EQA on AST for national public health laboratories on Salmonella (hereafter Salmonella EQA4-AST) within the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net).

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 May 2021 and includes updates on COVID-19, influenza, measles, Salmonella Braenderup, Ebola virus disease and cholera.

This technical report provides a summary of the evidence available at the time of the publication and what will be required in the future to support EU/EEA countries taking decisions on administration of the second dose, following a first dose of Vaxzevria. Since new evidence is being generated continuously and safety monitored on an ongoing basis, it is essential for readers to consider the latest available information.

ECDC’s influenza virus characterisation reports are published periodically and give an overview of circulating influenza viruses. They provide details on the current vaccine strains, summarise the development of the viruses since the last report, and closely follow the main developments for the ongoing influenza season. Virus characterisation reports are primarily intended for influenza virologists and epidemiologists.

Guidance on the gradual resumption of operations of cruise ships in the European Union in relation to the COVID-19 pandemic.

The aim of this Threat Assessment Brief is to assess potential public health implications of B.1.617 variants for EU/EEA countries, with a focus on lineage B.1.617.2.

On 24 May, ECDC upgraded B.1.617.2 to a variant of concern, after new information became available on increased transmissibility and some impact on vaccine effectiveness, especially after one vaccine dose. The suggestions highlighted in the Threat Assessment Brief regarding options for response remain valid, particularly vaccination rollout as a high priority to reduce COVID-19 mortality by vaccinating those at risk of severe illness in the shortest time possible.